8-K: Elevance Health Reports Mixed Q3 Results Amid Medicaid Challenges, Updates Full-Year Outlook

Elevance Health's third-quarter results show revenue growth offset by Medicaid membership losses and increased benefit expenses, leading to a revised full-year earnings outlook.

Summary

• Elevance Health reported a third-quarter operating revenue of $44.7 billion, a $2.2 billion increase year-over-year.
• The company's adjusted operating gain was $2.4 billion for the quarter.
• Diluted earnings per share (EPS) were $4.36, while adjusted diluted EPS reached $8.37.
• The benefit expense ratio increased to 89.5%, up 270 basis points, primarily due to a mismatch between Medicaid rates and member acuity.
• Medical membership decreased by 1.5 million, or 3%, to 45.8 million, mainly due to Medicaid attrition.
• The company repurchased 0.1 million shares for $60 million and paid $378 million in dividends.
• Elevance Health has increased its share repurchase authorization by $8.0 billion.
• The company now expects 2024 GAAP net income per diluted share to be approximately $26.50 and adjusted net income per diluted share to be approximately $33.00.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the revised full-year outlook, Medicaid challenges, and membership losses. However, the company is taking proactive steps to address these issues and has increased its share repurchase program, which provides some positive signals.

Positives

• Operating revenue increased by $2.2 billion year-over-year to $44.7 billion.
• Carelon segment operating revenue increased by 15% year-over-year, driven by growth in Carelon Services and CarelonRx.
• The operating expense ratio improved by 110 basis points to 11.8%, and the adjusted operating expense ratio improved by 150 basis points to 9.6%.
• Operating cash flow was $2.7 billion for the quarter, a slight increase year-over-year.
• The company increased its share repurchase authorization by $8.0 billion, indicating confidence in future cash flow.
• The company declared a fourth quarter dividend of $1.63 per share.

Negatives

• Medical membership decreased by 1.5 million, or 3%, primarily due to Medicaid attrition.
• The benefit expense ratio increased by 270 basis points to 89.5%, driven by Medicaid rate mismatches.
• Operating gain decreased by $0.4 billion year-over-year to $1.4 billion.
• Net income decreased by 22.5% year-over-year to $1.008 billion.
• The company has revised its full-year earnings outlook downwards, with GAAP net income per diluted share expected to be approximately $26.50 and adjusted net income per diluted share to be approximately $33.00.

Risks

• The company faces challenges in the Medicaid business due to a timing mismatch between rates and member acuity.
• Membership attrition in Medicaid is impacting overall medical membership.
• The company is exposed to risks related to healthcare costs, regulatory changes, and cyber-attacks.
• There are risks associated with maintaining and improving Medicare and Medicaid Star Ratings.
• The company faces competitive pressures and must adapt to industry changes.
• The company has a substantial amount of outstanding indebtedness and is exposed to interest rate risk.

Future Outlook

Elevance Health has revised its full-year 2024 outlook, now expecting GAAP net income per diluted share to be approximately $26.50 and adjusted net income per diluted share to be approximately $33.00. The company remains confident in its long-term earnings potential despite current challenges.

Management Comments

• We remain confident in the long-term earnings potential of our diverse businesses as we navigate a dynamic operating environment and unprecedented challenges in the Medicaid business.
• We expect Medicaid rates will align with the needs of our members in time, and are taking proactive actions to enhance operational efficiencies that will ensure we emerge from this period even stronger.

Industry Context

The healthcare industry is facing challenges related to Medicaid redeterminations and cost pressures. Elevance Health's results reflect these broader trends, with membership losses in Medicaid and increased benefit expenses impacting profitability. The company's focus on operational efficiencies and growth in other segments like Carelon is a common strategy in the industry to mitigate these challenges.

Comparison to Industry Standards

• Elevance Health's membership decline in Medicaid is consistent with trends seen across the industry due to eligibility redeterminations, with companies like Centene and Molina also reporting similar impacts.
• The increase in the benefit expense ratio is a common challenge for health insurers, with companies like UnitedHealth Group and Humana also facing pressure on medical costs.
• Elevance Health's focus on expanding its Carelon services is similar to strategies employed by other large health insurers to diversify revenue streams and improve profitability.
• The company's share repurchase program is a common capital allocation strategy among large, profitable healthcare companies, with companies like CVS Health and Cigna also actively repurchasing shares.

Stakeholder Impact

• Shareholders will be impacted by the revised earnings outlook and the decrease in net income.
• Employees may be affected by the company's efforts to enhance operational efficiencies.
• Customers may experience changes in service due to the company's focus on cost management.
• Suppliers and creditors may be impacted by the company's financial performance and capital allocation decisions.

Next Steps

• The company will continue to focus on enhancing operational efficiencies.
• Elevance Health intends to utilize the increased share repurchase authorization over a multi-year period.
• Management will host a conference call and webcast to discuss the results and outlook.

Key Dates

Keywords

Elevance Health, Healthcare, Medicaid, Health Benefits, Carelon, Operating Revenue, Earnings Per Share, Membership, Dividends, Share Repurchase, Financial Results